Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.22.2.2
SEGMENT INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information
The following table presents information by reportable operating segment for the three and nine months ended September 30, 2022 and 2021 (in thousands):
Consumer Products
Segment		 Specialty Pharmaceutical Segment Consolidated Totals
Three months ended September 30, 2022:
Product sales, net $ 3,751  $ —  $ 3,751 
Gross profit $ 1,562  $ —  $ 1,562 
Research and development expense 44  —  44 
Selling, general and administrative expense 2,409  1  2,410 
Operating loss $ (891) $ (1) $ (892)
Three months ended September 30, 2021:
Product sales, net $ 5,107  $ —  $ 5,107 
Gross profit $ 2,358  $ —  $ 2,358 
Research and development expense 126  284  410 
Selling, general and administrative expense 4,918  10  4,928 
Operating loss $ (2,686) $ (294) $ (2,980)

Consumer Products
Segment		 Specialty Pharmaceutical Segment Consolidated Totals
Nine months ended September 30, 2022:
Product sales, net $ 12,336  $ —  $ 12,336 
Gross profit $ 3,988  $ —  $ 3,988 
Research and development expense 246  21  267 
Selling, general and administrative expense 8,401  42  8,443 
Operating loss $ (4,659) $ (63) $ (4,722)
Nine months ended September 30, 2021:
Product sales, net $ 15,079  $ —  $ 15,079 
Gross profit $ 7,006  $ —  $ 7,006 
Research and development expense 380  441  821 
Selling, general and administrative expense 15,732  56  $ 15,788 
Operating loss $ (9,106) $ (497) $ (9,603)